FATE — FATE THERAPEUTICS INC

Ownership history in CAXTON ASSOCIATES LP  ·  5 quarters on record

This page tracks every 13F SEC filing in which CAXTON ASSOCIATES LP reported a position in FATE THERAPEUTICS INC (FATE). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.12% (2024 Q1)
Avg. % of fund
0.05%
First filed
2023 Q1
Last filed
2024 Q3
Quarters held
5
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2024 Q3 REDUCED 167,957 -4,906 -2.8% 0.02% $588K $3.50
2024 Q2 REDUCED 172,863 -117,324 -40.4% 0.02% $567K $3.28
2024 Q1 ADDED 290,187 +249,468 +612.7% 0.12% $2.1M $7.34
2023 Q2 REDUCED 40,719 -43,633 -51.7% 0.03% $194K $4.76
1 older quarter hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    FATE price (monthly, adj. close)

Other funds also holding FATE

As of 2025 Q4 — sorted by position size

Redmile Group, LLC 3Y 7Y 0.93% JOHNSON & JOHNSON 3Y 0.6% Bruce & Co., Inc. 3Y 7Y 0.22% Knott David M Jr 3Y 0.17% Monaco Asset Management SAM 3Y 0.14% DAFNA Capital Management LLC 3Y 7Y 0.13% Privium Fund Management B.V. 3Y 0.07% Vestal Point Capital, LP 0.06% TANG CAPITAL MANAGEMENT LLC 3Y 7Y 0.06% Parametrica Management Ltd 3Y 7Y 0.03%
← Back to CAXTON ASSOCIATES LP Holdings